These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33428273)

  • 1. The Antimicrobial Peptide Gad-1 Clears Pseudomonas aeruginosa Biofilms under Cystic Fibrosis Conditions.
    Portelinha J; Angeles-Boza AM
    Chembiochem; 2021 May; 22(9):1646-1655. PubMed ID: 33428273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Semi-Synthetic Peptide Lin-SB056-1 in Combination with EDTA Exerts Strong Antimicrobial and Antibiofilm Activity against Pseudomonas aeruginosa in Conditions Mimicking Cystic Fibrosis Sputum.
    Maisetta G; Grassi L; Esin S; Serra I; Scorciapino MA; Rinaldi AC; Batoni G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28926942
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Orazi G; O'Toole GA
    mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design SMAP29-LysPA26 as a Highly Efficient Artilysin against Pseudomonas aeruginosa with Bactericidal and Antibiofilm Activity.
    Wang T; Zheng Y; Dai J; Zhou J; Yu R; Zhang C
    Microbiol Spectr; 2021 Dec; 9(3):e0054621. PubMed ID: 34878337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.
    Lashua LP; Melvin JA; Deslouches B; Pilewski JM; Montelaro RC; Bomberger JM
    J Antimicrob Chemother; 2016 Aug; 71(8):2200-7. PubMed ID: 27231279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis.
    Charrier C; Rodger C; Robertson J; Kowalczuk A; Shand N; Fraser-Pitt D; Mercer D; O'Neil D
    Orphanet J Rare Dis; 2014 Nov; 9():189. PubMed ID: 25433388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
    Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
    J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competition in Biofilms between Cystic Fibrosis Isolates of
    Oluyombo O; Penfold CN; Diggle SP
    mBio; 2019 Jan; 10(1):. PubMed ID: 30696740
    [No Abstract]   [Full Text] [Related]  

  • 9. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
    Chang RYK; Das T; Manos J; Kutter E; Morales S; Chan HK
    AAPS J; 2019 Apr; 21(3):49. PubMed ID: 30949776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
    Fernández-Barat L; Ciofu O; Kragh KN; Pressler T; Johansen U; Motos A; Torres A; Hoiby N
    J Cyst Fibros; 2017 Mar; 16(2):222-229. PubMed ID: 27651273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial Peptides against Multidrug-Resistant
    Ben Hur D; Kapach G; Wani NA; Kiper E; Ashkenazi M; Smollan G; Keller N; Efrati O; Shai Y
    J Med Chem; 2022 Jul; 65(13):9050-9062. PubMed ID: 35759644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Smith S; Waters V; Jahnke N; Ratjen F
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa.
    Nagant C; Pitts B; Stewart PS; Feng Y; Savage PB; Dehaye JP
    Microbiologyopen; 2013 Apr; 2(2):318-25. PubMed ID: 23436807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B and ethylenediaminetetraacetic acid act synergistically against
    Hale SJM; Cameron AJ; Lux CA; Biswas K; Kim R; O'Carroll M; Harris PWR; Douglas RG; Wagner Mackenzie B
    Microbiol Spectr; 2024 Feb; 12(2):e0170923. PubMed ID: 38168683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Antibiotics against Pseudomonas aeruginosa in an
    Diaz Iglesias Y; Van Bambeke F
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.